Today the US Food and Drug Administration (FDA) approved secukinumab (Cosentyx) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.
All News
Article
Article
Dr. Cush reviews best reasons to go to ACR annually, but also the best way to learn ACR26 content this year.
Article
Obesity, in particular in psoriatic arthritis (PsA) was widely covered at #ACR26. This is from the recognition of the size of the problem.
Top 6 Practice-Changing Highlights from ACR26
The content at ACR Orlando was vast. We looked at several posters/listened to many talks, and heard from colleagues. So if we missed some great abstracts that will be practice-changing for you, we apologize in advance.
Here is our https://t.co/JmRpPh8Wzi
AI vs Rheumatologist? The Better Answer May Be Both
Can artificial intelligence answer patients’ rheumatology questions as well as a rheumatologist? Abstract 2965 at #ACR26 suggests the answer may be yes, but also highlights why physician oversight still matters. https://t.co/RNbCUFjMQo
ACR 2026 – Day 2 Report
https://t.co/H5aJMSwHwk https://t.co/gzGSaA9czB
anita
Tweet
@RheumNow The narrative medicine interactive session at #ACR2026 was well attended and had a lot of interesting exchange of thoughts and ideas. Holistic care of patients, attention to caregiver burnout and ensuring provider well being is the need of the hour in rheumatology.
Bella Mehta
Tweet
#ACR26 #2965: AI-generated answers to common pt Qs were rated similarly to rheumatologist-written answers. The highest-value approach, was AI plus rheumatologist review, which improved utility, readability, and completeness. The future may be hybrid, not human versus AI.@RheumNow
Akhil Sood MD, MS
Tweet
Inboxology: specialty needing more attention
Abstract 2951 quantified non-EHR visit time among pediatric rheumatologists
Vs national median:
1)patient msgs/day 5.1 vs 2.1
2)total inbasket time/day: 28.6 vs 14 mins
3)EHR time outside clinic/week: 322 vs 222 mins
@RheumNow #ACR26 https://t.co/20GG8EmwnU
anita
Tweet
@RheumNow Social determinants of health (SDOH) in rheumatology: Are we routinely screening for SDOH, and more importantly, how are we addressing the unmet needs identified? #ACR2026 Determinates of health and outcomes in rheumatic diseases #4
A#2944 ASAS Points to Consider for D2T and Rx-refractory axSpA:
Verify dx, rule out mimics, confirm inflammation with CRP/MRI, check adherence, address comorbidities, add non-pharm care, and provide education.
@RheumNow #ACR26 https://t.co/ETlqLSrj6J
anita
Tweet
@RheumNow Determinates of health and outcomes in Rheumatic diseases #3. Race & ethnicity in rheumatology guidelines: Clarify their role in recommendations, improve trial diversity to strengthen evidence, and do not restrict treatment options based on race or ethnicity. #ACR26
Fewer RA admissions, but more readmissions. US weighted index admissions fell 10541 in 2010 to 3901 in 2021; all-cause readmission rates rose 9.8% to 13.0%. Suggests hospitalized RA patients represent smaller but more medically complex population @Rheumnow #2924 #ACR26 https://t.co/WVUccpiELz
Bella Mehta
Tweet
Can AI answer our patients' rheumatology questions as well as we can?
In Abstract 2965 at #ACR26, patients rated AI and rheumatologist answers similarly. But expert-reviewed AI performed particularly well.
The human-in-the-loop may be the sweet spot. @RheumNow https://t.co/KWL7YPTnoG
How should race and ethnicity be used in rheumatology guidelines?
On the final day of #ACR26, I’ll discuss the evidence alongside Sam Lim and Candace Feldman.
Join us at 10-11am in W415A!
@RheumNow
https://t.co/VCHa4x5MlN https://t.co/KQKPmrxupf
Eric Dein
Tweet
Ab#2543 #ACR26 @RheumNow
Survey of US Academic Rheums on Opioid Rx
IMG trained - lower odds of opioid Rx
<5 yrs since training less likely to prescribe, 10-20 yrs OR 5.2, 20-30 yrs OR 6.7
60% felt opioids have role in rheum pain mgmt
70% feel pressured by pts
Dx: OA 41%, RA 28% https://t.co/Octn02lo3E
